Last reviewed 2026-04-23 · How we verify

Chemotherapy-Rituximab combination

Rituximab targets CD20 on B cells

Rituximab targets CD20 on B cells Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.

At a glance

Mechanism of action

Rituximab is a monoclonal antibody that binds to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent reduction in tumor burden.

Approved indications

• Non-Hodgkin's lymphoma
• Chronic lymphocytic leukemia

Common side effects

• Infusion-related reactions
• Neutropenia
• Thrombocytopenia

Key clinical trials

• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
• Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma (PHASE1)
• BNHL-2015 for Children or Adolescents in China (PHASE2, PHASE3)
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.